- PO (Adults): Adjunctive therapy (immediate-release): 300 mg twice daily, may ↑ by up to 600 mg/day at weekly intervals up to 1200 mg/day (up to 2400 mg/day may be needed); Conversion to monotherapy (immediate-release): 300 mg twice daily; may ↑ by 600 mg/day at weekly intervals, while other antiepileptic drugs are tapered over 3–6 wk; dose of oxcarbazepine should be ↑ up to 2400 mg/day over a period of 2–4 wk; Initiation of monotherapy (immediate-release): 300 mg twice daily, ↑ by 300 mg/day every 3rd day, up to 1200 mg/day. Maximum maintenance dose should be achieved over 2–4 wk; Adjunctive therapy or monotherapy (extended-release): 600 mg once daily for 1 wk; may ↑ by 600 mg/day at weekly intervals up to 1200–2400 mg once daily; Concurrent use of strong CYP3A4 inducer (carbamazepine, phenobarbital, phenytoin, rifampin) (extended-release): consider initiating therapy with 900 mg once daily.
- PO (Children 2–16 yr): Adjunctive therapy (immediate-release): 4–5 mg/kg twice daily (up to 600 mg/day), ↑ over 2 wk to achieve 900 mg/day in patients 20–29 kg, 1200 mg/day in patients 29.1–39 kg and 1800 mg/day in patients >39 kg (range 6–51 mg/kg/day). In patients <20 kg, initial dose of 16–20 mg/kg/day may be used not to exceed 60 mg/kg/day. Conversion to monotherapy (immediate-release): 8–10 mg/kg/day given twice daily; may ↑ by 10 mg/kg/day at weekly intervals, whereas other antiepileptic drugs are tapered over 3–6 wk; dose of oxcarbazepine should be ↑ up to 600–900 mg/day in patients ≤20 kg, 900–1200 mg/day in patients 25–30 kg, 900–1500 mg/day in patients 35–40 kg. 1200–1500 mg/day in patients 45 kg, 1200–1800 mg/day in patients 50–55 kg, 1200–2100 mg/day in patients 60–65 kg, and 1500–2100 mg/day in patients 70 kg. Maximum maintenance dose should be achieved over 2–4 wk.
- PO (Children 6–17 yr): Adjunctive therapy or monotherapy (extended-release): 8–10 mg/kg once daily (up to 600 mg/day) for 1 wk; may ↑ by 8–10 mg/kg/day at weekly intervals over 2–3 wk to achieve 900 mg/day in patients 20–29 kg, 1200 mg/day in patients 29.1–39 kg and 1800 mg/day in patients >39 kg; Concurrent use of strong CYP3A4 inducer (carbamazepine, phenobarbital, phenytoin, rifampin) (extended-release): consider initiating therapy with 12–15 mg/kg (max dose = 900 mg) once daily.
Renal Impairment
- PO (Adults): CCr<30 mL/min (immediate- and extended-release). Initiate therapy at 300 mg/day and ↑ slowly to achieve desired response.
